Unnamed: 0,title,date,stock,sentiment
1129296.0,"Sangamo Therapeutics Q1 EPS $(0.370) Misses $(0.290) Estimate, Sales $13.076M Miss $22.740M Estimate",2020-05-11 16:03:00-04:00,SGMO,negative
1129297.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,SGMO,neutral
1129298.0,Mogrify And Sangamo Announce Collaboration And Exclusive License Agreement For Mogrify's iPSC- And ESC-Derived Regulatory T Cells,2020-04-21 07:10:00-04:00,SGMO,positive
1129299.0,Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-07 07:48:00-04:00,SGMO,positive
1129300.0,15 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-04-07 07:38:00-04:00,SGMO,neutral
1129301.0,22 Stocks Moving in Tuesday's Pre-Market Session,2020-04-07 07:12:00-04:00,SGMO,neutral
1129302.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,SGMO,neutral
1129303.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,SGMO,negative
1129304.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,SGMO,negative
1129305.0,140 Biggest Movers From Friday,2020-03-02 04:43:00-05:00,SGMO,neutral
1129306.0,86 Stocks Moving In Friday's Mid-Day Session,2020-02-28 12:19:00-05:00,SGMO,negative
1129307.0,"Sangamo Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS results and sales up from last year. The company also announced a global collaboration with Biogen to develop gene regulation therapies for Alzheimer's, Parkinson's, and Neurimuscular.",2020-02-28 08:41:00-05:00,SGMO,positive
1129308.0,50 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-02-28 08:34:00-05:00,SGMO,neutral
1129309.0,46 Stocks Moving in Friday's Pre-Market Session,2020-02-28 07:39:00-05:00,SGMO,neutral
1129310.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,SGMO,neutral
1129311.0,"Sangamo Therapeutics Q4 EPS $(0.04) Beats $(0.33) Estimate, Sales $54.9M Up From $26.8M YoY",2020-02-28 07:03:00-05:00,SGMO,neutral
1129312.0,"Biogen And Sangamo Announce Global Collaboration To Develop Gene Regulation Therapies for Alzheimer's, Parkinson's, Neuromuscular And Other Neurological Diseases; Biogen To Pay Sangamo $350M Upfront, Sangamo Eligible For Up To $2.37B In Milestones",2020-02-27 16:10:00-05:00,SGMO,negative
1129313.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,SGMO,negative
1129314.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,SGMO,positive
1129315.0,Stocks That Hit 52-Week Lows On Wednesday,2020-02-26 11:14:00-05:00,SGMO,negative
1129316.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,SGMO,negative
1129317.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,SGMO,negative
1129318.0,43 Healthcare Stocks Moving In Tuesday's After-Market Session,2020-01-28 23:40:00-05:00,SGMO,neutral
1129319.0,Gene-editing/sequencing stocks trading higher following finalization of national coverage decision by Centers for Medicare & Medicaid Services related to next-gen sequencing.,2020-01-28 12:35:00-05:00,SGMO,neutral
1129320.0,"Sangamo Therapeutics shares are trading higher. The company announced early completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy IND, earning a $25 million milestone payment.",2019-12-23 11:50:00-05:00,SGMO,positive
1129321.0,Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment,2019-12-23 06:51:00-05:00,SGMO,neutral
1129322.0,Sangamo To Provide Updates At R&D Event Beginning At 8:00 a.m. ET; Co. Will Introduce New Gene Therapy And Genome Regulation Programs For Clinical Development With IND Targets In 2021 And 2022,2019-12-17 06:49:00-05:00,SGMO,neutral
1129323.0,13 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-12 07:37:00-05:00,SGMO,neutral
1129324.0,66 Biggest Movers From Yesterday,2019-12-11 04:52:00-05:00,SGMO,neutral
1129325.0,35 Stocks Moving In Tuesday's Mid-Day Session,2019-12-10 14:22:00-05:00,SGMO,neutral
1129326.0,Sangamo Therapeutics shares are trading lower on continued momentum after the company announced preliminary results from 3 patients in its Phase 1/2 study of ST-400.,2019-12-10 10:23:00-05:00,SGMO,neutral
1129327.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,SGMO,neutral
1129328.0,Sangamo Therapeutics shares are trading lower after the company announced preliminary results from 3 patients in its Phase 1/2 study of ST-400.,2019-12-09 15:30:00-05:00,SGMO,neutral
1129329.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-09 08:26:00-05:00,SGMO,neutral
1129330.0,Sangamo Gives Preliminary Results from 3 Patients in its Phase 1/2 Study of ST-400,2019-12-09 06:47:00-05:00,SGMO,neutral
1129331.0,Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment at ASH 2019,2019-12-07 14:29:00-05:00,SGMO,positive
1129332.0,63 Biggest Movers From Yesterday,2019-12-04 05:15:00-05:00,SGMO,neutral
1129333.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-12-03 12:20:00-05:00,SGMO,neutral
1129334.0,The Gene Therapy Names Moving On The Audentes Buyout Deal,2019-12-03 11:53:00-05:00,SGMO,neutral
1129335.0,Sangamo Therapeutics shares are trading higher in sympathy with Audentes Therapeutics after the company announced it will be acquired by Astellas Pharma for $60 per share in cash.,2019-12-03 09:29:00-05:00,SGMO,positive
1129336.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,SGMO,neutral
1129337.0,Sangamo Announces UK Authorization Of Phase 1/2 Clinical Trial Evaluating The CAR-Treg Cell Therapy TX200 For Kidney Transplantation,2019-11-19 07:13:00-05:00,SGMO,neutral
1129338.0,Sangamo Therapeutics Announces New Scientific Advisory Board,2019-11-08 08:36:00-05:00,SGMO,neutral
1129339.0,Sangamo Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.,2019-11-07 10:41:00-05:00,SGMO,positive
1129340.0,"Sangamo Therapeutics Q3 EPS $(0.24) Beats $(0.34) Estimate, Sales $21.958M Beat $12.16M Estimate",2019-11-06 16:53:00-05:00,SGMO,neutral
1129341.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,SGMO,positive
1129342.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,SGMO,neutral
1129343.0,Sangamo Therapeutics Names Sung Lee CFO,2019-11-01 08:08:00-04:00,SGMO,neutral
1129344.0,16 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-08-26 08:44:00-04:00,SGMO,neutral
1129345.0,"A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019",2019-07-09 11:10:00-04:00,SGMO,neutral
1129346.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, July 9, 2019",2019-07-09 09:49:00-04:00,SGMO,positive
1129347.0,"A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019",2019-07-08 13:50:00-04:00,SGMO,neutral
1129348.0,36 Stocks Moving In Monday's Mid-Day Session,2019-07-08 12:50:00-04:00,SGMO,neutral
1129349.0,Why Is Sangamo Therapeutics Moving?,2019-07-08 12:13:00-04:00,SGMO,neutral
1129350.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, July 8, 2019",2019-07-08 10:28:00-04:00,SGMO,positive
1129351.0,24 Stocks Moving In Monday's Pre-Market Session,2019-07-08 08:04:00-04:00,SGMO,neutral
1129352.0,Sangamo Therapeutics shares are trading higher after the company presented data from its Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A over the weekend.,2019-07-08 07:27:00-04:00,SGMO,negative
1129353.0,"Sangamo, Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels",2019-07-06 07:43:00-04:00,SGMO,positive
1129354.0,"The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight",2019-07-05 08:55:00-04:00,SGMO,negative
1129355.0,Sangamo Therapeutics Reports Nature Medicine Publication Detailing Activity Of Disease Allele-Selective Zinc Finger Proteins In Preclinical Models Of Huntington's Disease,2019-07-01 11:00:00-04:00,SGMO,neutral
1129356.0,The Week Ahead In Biotech: Pending Clinical Readouts In Focus,2019-06-29 08:25:00-04:00,SGMO,neutral
1129357.0,Sangamo Therapeutics Option Alert: Jul 19 $10 Calls Sweep (38) near the Ask: 782 @ $0.601 vs 2211 OI; Earnings 8/7 After Close [est] Ref=$9.77,2019-06-25 14:30:00-04:00,SGMO,positive
1129358.0,Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019,2019-06-21 09:24:00-04:00,SGMO,neutral
1129359.0,Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.,2019-05-31 10:25:00-04:00,SGMO,negative
1129360.0,82 Biggest Movers From Yesterday,2019-05-10 06:27:00-04:00,SGMO,neutral
1129361.0,71 Stocks Moving In Thursday's Mid-Day Session,2019-05-09 12:11:00-04:00,SGMO,neutral
1129362.0,Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.,2019-05-09 09:25:00-04:00,SGMO,neutral
1129363.0,"Sangamo BioSciences Q1 EPS $(0.41) Misses $(0.25) Estimate, Sales $8.071M Miss $22.82M Estimate",2019-05-08 16:36:00-04:00,SGMO,negative
1129364.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,SGMO,negative
1129365.0,52 Biggest Movers From Yesterday,2019-04-05 05:55:00-04:00,SGMO,neutral
1129366.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-04-04 12:39:00-04:00,SGMO,neutral
1129367.0,32 Stocks Moving In Thursday's Pre-Market Session,2019-04-04 08:18:00-04:00,SGMO,neutral
1129368.0,Sangamo Therapeutics Prices 11M Shares At $11.50/Share,2019-04-04 08:00:00-04:00,SGMO,positive
1129369.0,"The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut",2019-04-04 07:58:00-04:00,SGMO,neutral
1129370.0,"8 Stocks To Watch For April 4, 2019",2019-04-04 04:53:00-04:00,SGMO,neutral
1129371.0,Hearing Sangamo Just-Announced Offering Will Be Priced At $11.50/Share For Offering Size Of $115M,2019-04-03 16:25:00-04:00,SGMO,neutral
1129372.0,Sangamo Therapeutics Reports Proposed Common Stock Offering; Size No Disclosed,2019-04-03 16:01:00-04:00,SGMO,negative
1129373.0,"Benzinga Pro's Top 10 Most Searched Tickers For Morning Of Wed., Apr. 3, 2019",2019-04-03 09:58:00-04:00,SGMO,positive
1129374.0,54 Biggest Movers From Yesterday,2019-04-03 05:42:00-04:00,SGMO,neutral
1129375.0,Mid-Afternoon Market Update: ADMA Biologics Jumps On FDA Nod For Immunodeficiency Therapy; Evoke Pharma Shares Plummet,2019-04-02 14:38:00-04:00,SGMO,positive
1129376.0,Sangamo Soars Amid Multiple Development Pipeline Updates,2019-04-02 12:47:00-04:00,SGMO,neutral
1129377.0,Mid-Day Market Update: Crude Oil Up Over 1%; Apyx Medical Shares Slide,2019-04-02 12:38:00-04:00,SGMO,negative
1129378.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-04-02 12:27:00-04:00,SGMO,neutral
1129379.0,Hearing Sangamo Price Target Raised From $24 To New Street High Of $34 By Wells Fargo,2019-04-02 10:22:00-04:00,SGMO,positive
1129380.0,Mid-Morning Market Update: Markets Edge Lower; Walgreens Misses Q2 Views,2019-04-02 10:12:00-04:00,SGMO,negative
1129381.0,Sangamo Therapeutics shares are trading higher after the company announced positive Phase 1/2 interim data for its investigational Hemophilia gene therapy.,2019-04-02 09:23:00-04:00,SGMO,positive
1129382.0,UPDATE: Safety Monitoring Committee Recommended Cohort Expansion At The 3E13 Vg/Kg Dose Of SB-525,2019-04-02 07:07:00-04:00,SGMO,positive
1129383.0,Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy; SB-525 Was Well Tolerated And Demonstrated A Dose-Dependent Increase In Factor VIII (FVIII) Levels,2019-04-02 07:07:00-04:00,SGMO,positive
1129384.0,"Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update",2019-04-01 16:45:00-04:00,SGMO,neutral
1129385.0,Sangamo Therapeutics Option Alert: Apr 18 $10 Calls Sweep (2) near the Ask: 1886 @ $0.3 vs 2249 OI; Earnings 5/7 Before Open [est] Ref=$9.4539,2019-03-29 09:32:00-04:00,SGMO,positive
1129386.0,UPDATE: Sangamo Says 'Tau was reduced by greater than 80% in the brains of mice and nonhuman primates',2019-03-29 07:04:00-04:00,SGMO,positive
1129387.0,Sangamo Highlights Preclinical Data For ZFP-TFs Showing 'Significant' Reduction In Tau Expression With Gene Regulation Technology,2019-03-29 07:04:00-04:00,SGMO,neutral
1129388.0,Sangamo Therapeutics Earlier Highlighted Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing,2019-03-08 09:32:00-05:00,SGMO,neutral
1129389.0,81 Biggest Movers From Friday,2019-03-04 05:39:00-05:00,SGMO,neutral
1129390.0,Sangamo Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,2019-03-01 15:52:00-05:00,SGMO,positive
1129391.0,64 Stocks Moving In Friday's Mid-Day Session,2019-03-01 13:18:00-05:00,SGMO,neutral
1129392.0,"Sangamo Therapeutics Q4 EPS $(0.18) Beats $(0.21) Estimate, Sales $26.837M Beat $22.51M Estimate",2019-02-28 16:51:00-05:00,SGMO,neutral
1129393.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,SGMO,positive
1129394.0,Shares of gene therapy companies are trading higher after Roche announced it would acquire Spark Therapeutics for $114.50 per share in cash.,2019-02-25 09:38:00-05:00,SGMO,positive
1129395.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,SGMO,neutral
1129396.0,Sangamo Announces FDA Acceptance Of IND Application For ST-920 Gene Therapy Candidate For Fabry Disease,2019-02-20 07:35:00-05:00,SGMO,positive
1129397.0,"The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs",2019-02-08 09:17:00-05:00,SGMO,negative
1129398.0,72 Biggest Movers From Yesterday,2019-02-08 05:18:00-05:00,SGMO,neutral
1129399.0,Mid-Afternoon Market Update: Dow Down 1.1%; Chipotle Shares Jump Following Upbeat Q4 Results,2019-02-07 14:53:00-05:00,SGMO,positive
1129400.0,Sangamo Fails To Impress Investors With Genome Editing Studies,2019-02-07 13:43:00-05:00,SGMO,neutral
1129401.0,Sangamo Shares Tick Higher Over $8 Level As Hearing Wells Fargo Issued Mid-Day Defense On Stock/Co.,2019-02-07 12:48:00-05:00,SGMO,positive
1129402.0,54 Stocks Moving In Thursday's Mid-Day Session,2019-02-07 12:28:00-05:00,SGMO,neutral
1129403.0,Mid-Day Market Update: Crude Oil Down Over 3%; Solid Biosciences Shares Plunge,2019-02-07 12:07:00-05:00,SGMO,negative
1129404.0,Sangamo Therapeutics shares are trading lower after the company reported its SB-318 zinc finger nuclease genome editing product did not appear to show a clinical benefit in a Phase 1/2 trial.,2019-02-07 11:15:00-05:00,SGMO,positive
1129405.0,'First attempt at genome editing in U.S. patients produces disappointing — and sobering — results' -STAT News,2019-02-07 11:03:00-05:00,SGMO,negative
1129406.0,Sangamo Therapeutics Shares Halted On Circuit Breaker; Down 12.2%,2019-02-07 11:02:00-05:00,SGMO,positive
1129407.0,Sangamo Therapeutics Reports Results Of Phase 1/2 EMPOWERS Study Of SB-318 Zinc Finger Nuclease,2019-02-07 11:01:00-05:00,SGMO,neutral
1129408.0,"The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut",2019-02-07 08:08:00-05:00,SGMO,neutral
1129409.0,"The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs",2019-02-03 10:09:00-05:00,SGMO,neutral
1129410.0,"Jim Cramer Advises His Viewers On Brink's, Medtronic And More",2019-01-18 07:43:00-05:00,SGMO,neutral
1129411.0,28 Stocks Moving In Thursday's Pre-Market Session,2019-01-10 08:31:00-05:00,SGMO,neutral
1129412.0,56 Biggest Movers From Yesterday,2019-01-10 05:16:00-05:00,SGMO,neutral
1129413.0,Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B,2018-12-17 08:11:00-05:00,SGMO,neutral
1129414.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,SGMO,positive
1129415.0,76 Biggest Movers From Yesterday,2018-11-15 04:20:00-05:00,SGMO,neutral
1129416.0,58 Stocks Moving In Wednesday's Mid-Day Session,2018-11-14 12:49:00-05:00,SGMO,neutral
1129417.0,Sangamo Therapeutics shares down 16.0% following downgrade from JP Morgan; Analysts cited an 'undefined catalyst outlook',2018-11-14 11:40:00-05:00,SGMO,positive
1129418.0,8 Biggest Price Target Changes For Wednesday,2018-11-14 10:14:00-05:00,SGMO,neutral
1129419.0,"JP Morgan Maintains Neutral on Sangamo Therapeutics, Lowers Price Target to $11",2018-11-14 09:14:00-05:00,SGMO,positive
1129420.0,33 Stocks Moving In Wednesday's Pre-Market Session,2018-11-14 08:09:00-05:00,SGMO,neutral
1129421.0,"JP Morgan Downgrades Sangamo Therapeutics to Neutral, Lowers Price Target to $11",2018-11-14 06:36:00-05:00,SGMO,positive
1129422.0,"The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut",2018-11-13 07:54:00-05:00,SGMO,negative
1129423.0,85 Biggest Movers From Friday,2018-11-12 05:16:00-05:00,SGMO,neutral
1129424.0,68 Stocks Moving In Friday's Mid-Day Session,2018-11-09 12:42:00-05:00,SGMO,neutral
1129425.0,Sangamo Therapeutics shares are trading lower after the company announced it will not present initial SB-525 data at the ASH18 conference in December.,2018-11-09 10:19:00-05:00,SGMO,neutral
1129426.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Nov. 8, 2018",2018-11-09 09:38:00-05:00,SGMO,negative
1129427.0,"Benzinga's Top Upgrades, Downgrades For November 9, 2018",2018-11-09 09:02:00-05:00,SGMO,positive
1129428.0,Guggenheim Downgrades Sangamo Therapeutics to Neutral,2018-11-09 08:16:00-05:00,SGMO,neutral
1129429.0,"Sangamo BioSciences, Inc. Q3 EPS $(0.13) Beats $(0.15) Estimate, Sales $23.562M Miss $26.96M Estimate",2018-11-08 16:03:00-05:00,SGMO,negative
1129430.0,54 Biggest Movers From Yesterday,2018-09-06 05:13:00-04:00,SGMO,neutral
1129431.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Histogenics Shares Plunge,2018-09-05 14:32:00-04:00,SGMO,negative
1129432.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-09-05 12:40:00-04:00,SGMO,neutral
1129433.0,Mid-Day Market Update: NASDAQ Down Over 100 Points; ProQR Therapeutics Shares Surge,2018-09-05 12:04:00-04:00,SGMO,positive
1129434.0,Mid-Morning Market Update: Markets Open Lower; HD Supply Earnings Top Expectations,2018-09-05 10:29:00-04:00,SGMO,negative
1129435.0,Sangamo Shares Sink After Data Release For Gene Editing Product Candidate,2018-09-05 09:44:00-04:00,SGMO,positive
1129436.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,SGMO,positive
1129437.0,"Sangamo Says Will Host Conference Call, Webcast To Discuss SB-913 At 9 a.m. EDT Wed.",2018-09-05 08:19:00-04:00,SGMO,neutral
1129438.0,UPDATE: Sangamo Highlights 'SB-913 has been generally well-tolerated with no treatment related serious adverse events in patients up to 32 weeks',2018-09-05 08:18:00-04:00,SGMO,negative
1129439.0,"UPDATE: Sangamo Highlights 'Total urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks'",2018-09-05 08:18:00-04:00,SGMO,neutral
1129440.0,"Sangamo Therapeutics Highlights Presentation At Annual Symposium of the Society for the Study of Inborn Errors of Metabolism Evaluating SB-913 Which Showed Early Data From Cohorts 1, 2, Enrollment Of Cohort 3 Recently Completed",2018-09-05 08:17:00-04:00,SGMO,negative
1129441.0,Sangamo Therapeutics Option Alert: Sep 21 $20 Calls at the Ask: 600 @ $1.7 vs 8905 OI; Ref=$18.35,2018-09-04 13:02:00-04:00,SGMO,positive
1129442.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2018-09-02 09:41:00-04:00,SGMO,neutral
1129443.0,77 Biggest Movers From Yesterday,2018-08-10 04:01:00-04:00,SGMO,neutral
1129444.0,68 Stocks Moving In Thursday's Mid-Day Session,2018-08-09 12:41:00-04:00,SGMO,neutral
1129445.0,"The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings",2018-08-09 08:39:00-04:00,SGMO,positive
1129446.0,Sangamo Therapeutics Reports Prelim. Data From Phase 1/2 Alta Study Evaluating SB-525: 'has been generally well tolerated',2018-08-08 16:59:00-04:00,SGMO,positive
1129447.0,"Sangamo BioSciences Q2 EPS $(0.17) Misses $(0.15) Estimate, Sales $21.416M Miss $21.43M Estimate; Expects To Have Cash, Cash Equivalents, Marketable Securities, Interest Receivable Of At Least $380M At End Of 2018",2018-08-08 16:57:00-04:00,SGMO,positive
1129448.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,SGMO,positive
1129449.0,"Sangamo Announces TxCell Acquisition, Patient Dosing In SB-318",2018-07-23 11:35:00-04:00,SGMO,neutral
1129450.0,Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Evaluating SB-318,2018-07-23 07:01:00-04:00,SGMO,neutral
1129451.0,A Peek Into The Markets: US Stock Futures Down; Alphabet Earnings In Focus,2018-07-23 06:53:00-04:00,SGMO,neutral
1129452.0,Sangamo Therapeutics to Acquire TxCell for €2.58/Share in Cash,2018-07-23 03:40:00-04:00,SGMO,neutral
1129453.0,50 Biggest Movers From Yesterday,2018-06-21 04:34:00-04:00,SGMO,neutral
1129454.0,38 Stocks Moving In Wednesday's Mid-Day Session,2018-06-20 12:23:00-04:00,SGMO,neutral
1129455.0,"Benzinga's Top Upgrades, Downgrades For June 20, 2018",2018-06-20 09:20:00-04:00,SGMO,positive
1129456.0,"Bank of America Initiates Coverage On Sangamo Therapeutics with Buy Rating, Announces $24 Price Target",2018-06-20 07:29:00-04:00,SGMO,neutral
1129457.0,"Adam Feuerstein Tweets: BREAKING --> A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies https://www.statnews.com/2018/06/11/crispr-hurdle-edited-cells-might-cause-cancer/ … via @sxbegle $CRSP $EDIT $NTLA $SGMO",2018-06-11 11:05:00-04:00,SGMO,negative
1129458.0,Sangamo Announces UK Authorization Of Clinical Trials Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatments,2018-06-04 08:22:00-04:00,SGMO,neutral
1129459.0,"Bioverativ, Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease",2018-05-16 07:31:00-04:00,SGMO,positive
1129460.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,SGMO,neutral
1129461.0,"Sangamo BioSciences Q1 EPS $(0.23) Does Not Compare To $0.48 Estimate, Sales $12.63M Does Not Compare To $53.09M Estimate",2018-05-08 07:13:00-04:00,SGMO,neutral
1129462.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,SGMO,neutral
1129463.0,"Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings",2018-05-01 07:51:00-04:00,SGMO,neutral
1129464.0,Sangamo Announces $8M CIRM Grant For ST-400,2018-04-27 08:31:00-04:00,SGMO,positive
1129465.0,Sangamo Therapeutics Prices 12.31M Share Public Offering of Common Stock @$16.25/Share,2018-04-26 04:02:00-04:00,SGMO,positive
1129466.0,24 Stocks Moving In Wednesday's Pre-Market Session,2018-04-25 08:02:00-04:00,SGMO,neutral
1129467.0,"Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen",2018-04-25 07:46:00-04:00,SGMO,negative
1129468.0,"15 Stocks To Watch For April 25, 2018",2018-04-25 04:04:00-04:00,SGMO,neutral
1129469.0,Sangamo Therapeutics Shares Down 7.0% After Hours Following Announcement Of $200M Common Stock Offering,2018-04-24 17:22:00-04:00,SGMO,positive
1129470.0,Sangamo Therapeutics Announces $200M Public Offering,2018-04-24 16:05:00-04:00,SGMO,neutral
1129471.0,24 Stocks Moving In Monday's Pre-Market Session,2018-04-23 08:02:00-04:00,SGMO,neutral
1129472.0,"UPDATE: Sangamo Says Investigation Did Not Reveal Evidence Co.'s Network, Other IT Systems Were Otherwise Compromised",2018-04-17 16:11:00-04:00,SGMO,neutral
1129473.0,"UPDATE: Sangamo Says Upon Learning Of Data Security Incident, External Network Security Experts Were Promptly Engaged",2018-04-17 16:10:00-04:00,SGMO,positive
1129474.0,Sangamo Therapeutics 8-K Shows Data Security Incident Which Compromised A Senior Execs Email Account,2018-04-17 16:10:00-04:00,SGMO,positive
1129475.0,Sangamo Option Alert: Apr 20 $21 Calls at the Bid: 879 @ $0.451 vs 423 OI; Earnings 5/9 After Close [est] Ref=$19.35,2018-04-11 10:33:00-04:00,SGMO,positive
1129476.0,UPDATE: Sangamo Says 'Study provided proof of concept for development of SB-913 product candidate currently being evaluated in Phase 1/2 clinical trial',2018-04-04 07:31:00-04:00,SGMO,neutral
1129477.0,Sangamo Therapeutics Reports Publication In Molecular Therapy Preclinical Study Data From MPS II In Vivo Genome Editing Program,2018-04-04 07:31:00-04:00,SGMO,neutral
1129478.0,38 Biggest Movers From Yesterday,2018-03-28 05:19:00-04:00,SGMO,neutral
1129479.0,Sangamo Reports U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatment For Hemophilia B,2018-02-28 07:30:00-05:00,SGMO,neutral
1129480.0,56 Biggest Movers From Yesterday,2018-02-23 05:17:00-05:00,SGMO,neutral
1129481.0,Mid-Afternoon Market Update: Crude Oil Up Over 1.5%; Whiting Petroleum Shares Climb After Strong Q4 Results,2018-02-22 14:30:00-05:00,SGMO,positive
1129482.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-02-22 12:26:00-05:00,SGMO,neutral
1129483.0,Mid-Day Market Update: Dow Rises Over 1%; Applied Optoelectronics Shares Plummet,2018-02-22 12:05:00-05:00,SGMO,positive
1129484.0,"Sangamo Therapeutics Shares Up 19.8% After Deal With Gilead For Oncology-Focused Cell Therapies, Better-Than-Expected Q4 Results",2018-02-22 11:59:00-05:00,SGMO,positive
1129485.0,Mid-Morning Market Update: Markets Open Higher; PPL Profit Tops Expectations,2018-02-22 10:13:00-05:00,SGMO,positive
1129486.0,30 Stocks Moving In Thursday's Pre-Market Session,2018-02-22 07:54:00-05:00,SGMO,neutral
1129487.0,"Sangamo Therapeutics Reports Q4 EPS $(0.15) vs $(0.18) est., Sales $13.1M vs $11.4M Est.",2018-02-22 07:11:00-05:00,SGMO,neutral
1129488.0,"Gilead's Kite, Sangamo Therapeutics Partner To Develop Generation Engineered Cell Therapies For Cancer Treatment, Sangamo To Receive Upfront Payment Of $150M With $3.01B In Potential Milestone Payments",2018-02-22 07:10:00-05:00,SGMO,negative
1129489.0,Sangamo Therapeutics Announces an $11 Million Grant Fro the National Institute of Health for Study of Gene-Edited T Cells for Viral Eradication of HIV,2018-02-07 07:39:00-05:00,SGMO,positive
1129490.0,Sangamo Option Alert: Feb 16 $20 Puts Sweep (29) at the Ask: 2915 @ $2.101 vs 468 OI; Earnings 2/27 Before Open [est] Ref=$19.75,2018-01-24 11:24:00-05:00,SGMO,positive
1129491.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-01-24 08:14:00-05:00,SGMO,neutral
1129492.0,28 Stocks Moving In Tuesday's Pre-Market Session,2018-01-23 08:02:00-05:00,SGMO,neutral
1129493.0,38 Biggest Movers From Yesterday,2018-01-23 04:55:00-05:00,SGMO,neutral
1129494.0,32 Stocks Moving In Monday's Mid-Day Session,2018-01-22 12:46:00-05:00,SGMO,neutral
1129495.0,30 Stocks Moving In Monday's Pre-Market Session,2018-01-22 07:58:00-05:00,SGMO,neutral
1129496.0,Sangamo to Receive a $12M Upfront Payment From Pfizer For a Collaboration On Zinc Finger Protein Gene Therapy for ALS,2018-01-03 07:33:00-05:00,SGMO,neutral
1129497.0,"Shares Of Gene Therapy Development Stocks Showing Strength Tuesday: CRSP +7.2%, EDIT +10.22%, SGMO +7.01%, BOLD +4.8%",2018-01-02 14:47:00-05:00,SGMO,positive
1129498.0,4 Biotech Stocks Ready To Crush The Market In 2018,2017-12-27 12:41:00-05:00,SGMO,positive
1129499.0,The Companies That Led 2017's Biotech Rally,2017-12-22 09:50:00-05:00,SGMO,neutral
1129500.0,Sangamo Option Alert: Feb 16 $20 Calls Sweep (3) at the Bid: 1541 @ $1.554 vs 99 OI; Ref=$17.1 Signals,2017-12-08 11:33:00-05:00,SGMO,positive
1129501.0,"Sangamo Therapeutics Reports EMA Recommended Orphan Medicinal Product Designation For Investigational Genome Editing Treatments for MPS I, II",2017-12-07 16:25:00-05:00,SGMO,positive
1129502.0,"Sangamo Therapeutics Make New 52-week High $18.40, Now Up 4.23% At $17.25",2017-12-04 14:14:00-05:00,SGMO,neutral
1129503.0,4 Biotech Stocks To Better Your Financial Health This Winter,2017-12-04 12:25:00-05:00,SGMO,positive
1129504.0,38 Biggest Movers From Yesterday,2017-12-01 04:44:00-05:00,SGMO,neutral
1129505.0,"Benzinga's Top Upgrades, Downgrades For November 22, 2017",2017-11-22 09:10:00-05:00,SGMO,positive
1129506.0,"Barclays Initiates Coverage On Sangamo Therapeutics with Overweight Rating, Announces $20.00 Price Target",2017-11-22 08:30:00-05:00,SGMO,negative
1129507.0,40 Biggest Movers From Yesterday,2017-11-16 04:46:00-05:00,SGMO,neutral
1129508.0,33 Stocks Moving In Wednesday's Mid-Day Session,2017-11-15 12:32:00-05:00,SGMO,neutral
1129509.0,"Benzinga's Top Upgrades, Downgrades For November 15, 2017",2017-11-15 09:13:00-05:00,SGMO,positive
1129510.0,PiperJaffray Upgrades Sangamo Therapeutics to Overweight,2017-11-15 07:19:00-05:00,SGMO,negative
1129511.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-11-15 07:08:00-05:00,SGMO,neutral
1129512.0,Sangamo Announces First Patient Treated in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II,2017-11-15 04:06:00-05:00,SGMO,positive
1129513.0,44 Biggest Movers From Friday,2017-11-13 05:41:00-05:00,SGMO,neutral
1129514.0,35 Stocks Moving In Friday's Mid-Day Session,2017-11-10 12:41:00-05:00,SGMO,neutral
1129515.0,Sangamo Announces Strategic Investment In Manufacturing,2017-11-09 16:12:00-05:00,SGMO,neutral
1129516.0,"Sangamo Therapeutics Reports Q3 EPS $(0.15) vs $(0.19) Est., Sales $11.812M",2017-11-09 16:02:00-05:00,SGMO,neutral
1129517.0,Barclays: Editas Medicine On Track To File New Drug App Next Year,2017-11-08 16:24:00-05:00,SGMO,neutral
1129518.0,"Lightning Round: Jim Cramer Gives His Opinion On Delta, Sangamo, Kinder Morgan And More",2017-10-18 07:45:00-04:00,SGMO,positive
1129519.0,25 Stocks Moving In Friday's Pre-Market Session,2017-10-06 08:14:00-04:00,SGMO,neutral
1129520.0,"Sangamo, Bioverativ Report FDA Acceptance Of IND Application For ST-400",2017-10-02 07:32:00-04:00,SGMO,positive
1129521.0,"Genome Editing Stocks Strong This Morning, Not Seeing Any News: Intellia Therapeutics Shares Up 9%, Editas Up 4.5%, Sangamo Up 0.6%, Cellectis Up 0.2%; 1 Outlier Is Crispr Therapeutics, Down 1% For Session",2017-09-21 11:07:00-04:00,SGMO,positive
1129522.0,"Secondary Offering Lockup Expirations Today From Determine, Sangamo Therapeutics, Avexis, and Valeritas",2017-09-19 09:19:00-04:00,SGMO,neutral
1129523.0,25 Stocks Moving In Monday's Pre-Market Session,2017-08-28 08:16:00-04:00,SGMO,neutral
1129524.0,"Sangamo Therapeutics, Pfizer Report First Patient Received Treatment In Phase 1/2 Trial Evaluating SB-525",2017-08-25 08:02:00-04:00,SGMO,neutral
1129525.0,Mid-Day Market Update: Aegean Marine Rises After Q2 Results; Black Box Shares Plunge,2017-08-11 12:01:00-04:00,SGMO,positive
1129526.0,"Sangamo Therapeutics Reports Q2 EPS $(0.17) vs $(0.19) Est., Sales $8.3M vs $6M Est.",2017-08-09 16:02:00-04:00,SGMO,neutral
1129527.0,15 Biggest Mid-Day Gainers For Friday,2017-07-14 12:32:00-04:00,SGMO,neutral
1129528.0,25 Stocks Moving In Friday's Pre-Market Session,2017-07-14 08:11:00-04:00,SGMO,neutral
1129529.0,Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913,2017-07-13 16:01:00-04:00,SGMO,neutral
1129530.0,"Benzinga's Bulls & Bears For The Past Week: Netflix, AMD, Colgate And More",2017-06-25 14:33:00-04:00,SGMO,neutral
1129531.0,6 Biotech Stocks Jefferies Says Are Undervalued,2017-06-23 09:21:00-04:00,SGMO,neutral
1129532.0,Mid-Afternoon Market Update: Steelcase Tumbles Following Disappointing Earnings Report; Staples Shares Surge,2017-06-22 14:32:00-04:00,SGMO,negative
1129533.0,Mid-Day Market Update: Oracle Surges On Earnings Beat; Kamada Shares Plummet,2017-06-22 12:01:00-04:00,SGMO,positive
1129534.0,Mid-Morning Market Update: Markets Mostly Flat; Accenture Posts In-Line Q3 Earnings,2017-06-22 10:09:00-04:00,SGMO,neutral
1129535.0,12 Biggest Mid-Day Losers For Wednesday,2017-06-21 12:50:00-04:00,SGMO,negative
1129536.0,Mid-Morning Market Update: Markets Mostly Higher; CarMax Tops Q1 Expectations,2017-06-21 10:11:00-04:00,SGMO,positive
1129537.0,20 Stocks Moving In Wednesday's Pre-Market Session,2017-06-21 08:32:00-04:00,SGMO,neutral
1129538.0,Sangamo Therapeutics Prices 10M Shares At $7.25/Share,2017-06-21 08:28:00-04:00,SGMO,positive
1129539.0,"Sangamo Therapeutics Reports Offering Of Common Shares, Amount Not Disclosed",2017-06-20 16:01:00-04:00,SGMO,positive
1129541.0,"Sangamo Therapeutics, Pfizer Report SB-525 Received Orphan Medicinal Production Designation from EMA",2017-06-07 07:31:00-04:00,SGMO,neutral
1129542.0,Benzinga's Option Alert Recap From May 23,2017-05-23 16:36:00-04:00,SGMO,positive
1129543.0,Option Alert: Sangamo Jun 7.0 Calls Sweep: 865 @  ASK  $0.998: 2055 traded vs 1407 OI:  Earnings 8/2 After Close (est)  $7.65 Ref,2017-05-23 10:57:00-04:00,SGMO,positive
1129544.0,Benzinga's Option Alert Recap From May 16,2017-05-16 16:59:00-04:00,SGMO,positive
1129545.0,Option Alert: Sangamo May 8.0 Puts Sweep: 500 @  ASK  $0.40: 1043 traded vs 600 OI:  Earnings 8/2 After Close (est)  $7.89 Re,2017-05-16 09:58:00-04:00,SGMO,positive
1129546.0,Sangamo Gets Fast Track Designation for SB-525,2017-05-16 07:36:00-04:00,SGMO,neutral
1129547.0,Mid-Afternoon Market Update: Inpixon Drops Following Q1 Results; Technical Communications Shares Spike Higher,2017-05-12 14:30:00-04:00,SGMO,positive
1129548.0,15 Biggest Mid-Day Gainers For Friday,2017-05-12 12:26:00-04:00,SGMO,neutral
1129549.0,Mid-Afternoon Market Update: Crude Oil Up 1.25%; Straight Path Shares Plunge,2017-05-11 14:33:00-04:00,SGMO,negative
1129550.0,12 Biggest Mid-Day Gainers For Thursday,2017-05-11 12:22:00-04:00,SGMO,neutral
1129551.0,Mid-Day Market Update: Snap Tumbles After Q1 Report; Sangamo Shares Surge,2017-05-11 12:02:00-04:00,SGMO,positive
1129552.0,Mid-Morning Market Update: Markets Open Lower; Macy's Profit Misses Expectations,2017-05-11 10:05:00-04:00,SGMO,negative
1129553.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-05-11 08:17:00-04:00,SGMO,neutral
1129554.0,"Sangamo+40% Premarket @$6.10 Following Wednesday Earnings Report, Co Announced Strategic Collaboration with Pfizer for Hemophilia A Phase 1/2 Therapy Program",2017-05-11 07:32:00-04:00,SGMO,neutral
1129555.0,"Sangamo Shares Resume, Now Up 42%",2017-05-10 16:35:00-04:00,SGMO,positive
1129556.0,Sangamo Shares to Resume Trade at 4:30 p.m. EDT,2017-05-10 16:25:00-04:00,SGMO,positive
1129557.0,Sangamo Reports Strategic Collaboration with Pfizer for Hemophilia A Phase 1/2 Therapy Program,2017-05-10 16:04:00-04:00,SGMO,neutral
1129558.0,"Sangamo Therapeutics Reports Q1 EPS $(0.23) vs $(0.26) Est., Sales $3.4M vs $4.3M Est.",2017-05-10 16:03:00-04:00,SGMO,neutral
1129559.0,Sangamo Shares Halted News Pending,2017-05-10 16:00:00-04:00,SGMO,positive
1129560.0,"Sangamo Therapeutics Reports Special Regulatory Designations from the FDA For SB-913, SB-525, & SB-FIX",2017-05-04 08:10:00-04:00,SGMO,positive
1129561.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-03-30 08:21:00-04:00,SGMO,neutral
1129562.0,18 Biggest Mid-Day Gainers For Wednesday,2017-03-29 12:46:00-04:00,SGMO,neutral
1129563.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-03-29 08:39:00-04:00,SGMO,neutral
1129564.0,"Sangamo Therapeutics Reports Presentation of New Data Showing 'significant reduction of tau mRNA, tau protein expression using ZFP-TF-mediated gene regulation technology'",2017-03-29 07:34:00-04:00,SGMO,positive
1129565.0,Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913,2017-03-01 08:32:00-05:00,SGMO,neutral
1129566.0,"Sangamo Therapeutics Reports Q4 EPS $(0.14) vs. $(0.25) Est., Sales $8.92M",2017-02-28 07:06:00-05:00,SGMO,neutral
1129567.0,"Sangamo Therapeutics Reports CFO H. Ward Wolff To Retire, Kathy Yi Named Successor",2017-02-27 16:33:00-05:00,SGMO,positive
1129568.0,22 Stocks Moving In Monday's Pre-Market Session,2017-02-27 08:20:00-05:00,SGMO,neutral
1129569.0,Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318,2017-02-27 08:04:00-05:00,SGMO,neutral
1129570.0,Your Guide To 2017's Emerging Pharmaceuticals Catalysts,2017-02-07 14:39:00-05:00,SGMO,neutral
1129571.0,Hemophilia Fighter Bioverativ Launches On NASDAQ,2017-02-02 15:41:00-05:00,SGMO,positive
1129572.0,Mid-Afternoon Market Update: Dow Slides Over 100 Points; CSX Shares Spike Higher,2017-01-19 14:44:00-05:00,SGMO,positive
1129573.0,Mid-Day Market Update: Oclaro Surges Following Strong Q2 Outlook; Zynerba Pharmaceuticals Shares Decline,2017-01-19 12:32:00-05:00,SGMO,positive
1129574.0,Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Tops Q4 Estimates,2017-01-17 09:57:00-05:00,SGMO,positive
1129575.0,12 Biggest Mid-Day Gainers For Friday,2017-01-13 12:16:00-05:00,SGMO,neutral
1129576.0,18 Stocks Moving In Friday's Pre-Market Session,2017-01-13 08:08:00-05:00,SGMO,neutral
1129577.0,15 Biggest Mid-Day Gainers For Wednesday,2017-01-11 12:35:00-05:00,SGMO,neutral
1129578.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-01-11 08:22:00-05:00,SGMO,neutral
1129579.0,Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318,2017-01-11 07:30:00-05:00,SGMO,neutral
1129580.0,18 Biggest Mid-Day Losers For Thursday,2017-01-05 13:03:00-05:00,SGMO,negative
1129581.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-01-05 08:23:00-05:00,SGMO,neutral
1129582.0,Sangamo BioSciences Gets FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A,2017-01-05 08:04:00-05:00,SGMO,neutral
1129583.0,13 Emerging Biotechs With Catalysts In 2017,2017-01-03 14:22:00-05:00,SGMO,neutral
1129584.0,Mid-Afternoon Market Update: Worthington Drops On Earnings Miss; Fred's Shares Spike Higher,2016-12-20 14:34:00-05:00,SGMO,positive
1129585.0,Mid-Afternon Market Update: Restoration Hardware Tumbles On Weak Guidance; Stillwater Mining Shares Spike Higher,2016-12-09 14:36:00-05:00,SGMO,negative
1129586.0,Mid-Morning Market Update: Markets Open Higher; Finisar Beats Q2 Estimates,2016-12-09 10:07:00-05:00,SGMO,neutral
1129587.0,Mid-Morning Market Update: Markets Edge Lower; Ciena Profit Misses Estimates,2016-12-08 10:19:00-05:00,SGMO,negative
1129588.0,Sangamo BioSciences Presents Hemophilia A Program Data at ASH 2016,2016-12-05 21:07:00-05:00,SGMO,neutral
1129589.0,"Sangamo BioSciences Restructuring Creates A Pipeline Gap, Merits 87% PT Decrease",2016-11-01 11:13:00-04:00,SGMO,positive
1129590.0,Stocks Hitting 52-Week Lows,2016-11-01 10:36:00-04:00,SGMO,negative
1129591.0,7 Biggest Price Target Changes For Tuesday,2016-11-01 09:47:00-04:00,SGMO,neutral
1129592.0,Benzinga's Top Downgrades,2016-11-01 09:15:00-04:00,SGMO,positive
1129593.0,"Wedbush Downgrades Sangamo BioSciences, Inc. - Common Stock to Neutral, Lowers to $4.00",2016-11-01 06:09:00-04:00,SGMO,negative
1129594.0,"Sangamo BioSciences Reports Q3 Loss/Share $0.27 vs Est Loss/Share Of $0.25, Rev $2.8M",2016-10-26 16:54:00-04:00,SGMO,neutral
1129595.0,Mid-Afternoon Market Update: Imperva Tumbles Amid Sale Concerns; Banc of California Shares Surge,2016-10-19 14:58:00-04:00,SGMO,positive
1129596.0,15 Biggest Mid-Day Losers For Wednesday,2016-10-19 12:36:00-04:00,SGMO,negative
1129597.0,Mid-Day Market Update: Crude Oil Up 2.75%; Cerulean Pharma Shares Surge On News Of Novartis Collaboration,2016-10-19 12:02:00-04:00,SGMO,negative
1129598.0,"PiperJaffray Downgrades Sangamo BioSciences, Inc. - Common Stock to Neutral",2016-10-19 11:11:00-04:00,SGMO,neutral
1129599.0,16 Stocks Moving In Wednesday's Pre-Market Session,2016-10-19 08:20:00-04:00,SGMO,neutral
1129600.0,Mid-Afternoon Market Update: Crude Oil Down Over 1%; VOXX Shares Spike Higher,2016-10-12 15:13:00-04:00,SGMO,negative
1129601.0,"Jefferies Gene Editing/Gene Therapy Summit Commences Today With Presenters Including bluebird bio, Audentes Therapeutics, Spark Therapeutics, Sangamo Biosciences, And uniQure",2016-10-11 08:23:00-04:00,SGMO,positive
1129602.0,12 Biggest Mid-Day Gainers For Tuesday,2016-09-06 12:46:00-04:00,SGMO,neutral
1129603.0,15 Stocks Moving In Tuesday's Pre-Market Session,2016-09-06 08:22:00-04:00,SGMO,neutral
1129604.0,Sangamo BiosSciences Gets orphan Drug Designation For SB-FIX,2016-09-06 07:04:00-04:00,SGMO,neutral
1129605.0,Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX,2016-09-06 07:01:00-04:00,SGMO,neutral
1129606.0,20 Biggest Mid-Day Losers For Thursday,2016-08-04 13:05:00-04:00,SGMO,negative
1129607.0,Mid-Day Market Update: Crude Oil Rises Over 2%; Sangamo Biosciences Drops Following Weak Q2 Results,2016-08-04 12:18:00-04:00,SGMO,negative
1129608.0,Mid-Morning Market Update: Markets Edge Lower; Viacom Tops Q3 Expectations,2016-08-04 10:05:00-04:00,SGMO,positive
1129609.0,Benzinga's Top Downgrades,2016-08-04 09:23:00-04:00,SGMO,positive
1129610.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-08-04 08:35:00-04:00,SGMO,neutral
1129611.0,Janney Capital Downgrades Sangamo BioSciences to Neutral,2016-08-04 07:25:00-04:00,SGMO,neutral
1129612.0,"After-Hours Losers Aug. 3, '16: TDOC Down 24%, SGMO 18.4%, BSQR 15.9%, TEGP 14.7%, FRSH 14.4%, BBRG 13.9%, INOV 13.9%, ADAP 12.9%",2016-08-03 19:14:00-04:00,SGMO,negative
1129613.0,Sangamo BioSciences Reports Q2 Rev. $3.7M vs. Est. $5.3M,2016-08-03 16:45:00-04:00,SGMO,neutral
1129614.0,Sangamo Biosciences Reports Q2 EPS $(0.38) vs. Est. $(0.24),2016-08-03 16:45:00-04:00,SGMO,neutral
1129615.0,Sangamo BioSciences Reveals New Gene Therapy Clinical Development Program For Hemophilia A Treatment,2016-07-26 12:56:00-04:00,SGMO,neutral
1129616.0,"UPDATE: Sangamo Says Will Update Guidance for In Vivo Genome Editing Approach for Hemophilia A, Other Programs During Q2 Earnings Conference Call",2016-07-26 11:48:00-04:00,SGMO,neutral
1129617.0,UPDATE: Sangamo Sees Filing Investigational NDA for New Factor VIII Gene Therapy Approach in '16,2016-07-26 11:47:00-04:00,SGMO,neutral
1129618.0,Sangamo Biosciences Reports New Gene Therapy Clinical Developmen Program for Treatment of Hemophilia A,2016-07-26 11:47:00-04:00,SGMO,neutral
1129619.0,Sangamo BioSciences Gets FDA Approval For IND For ZFN-Mediated Genome Editing Treatment Of MPS II,2016-06-20 07:58:00-04:00,SGMO,positive
1129620.0,Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II,2016-06-20 07:02:00-04:00,SGMO,neutral
1129621.0,"Sangamo Biosciences CEO Edward Lanphier To Retire, Names Sandy Macrae Successor",2016-06-01 07:13:00-04:00,SGMO,positive
1129622.0,Sangamo Biosciences Announces CEO to Retire,2016-06-01 07:05:00-04:00,SGMO,neutral
1129623.0,Sangamo Reaffirms FY16 Sales $20M-$25M vs $22.8M Est.,2016-05-02 16:36:00-04:00,SGMO,neutral
1129624.0,"Sangamo Biosciences Reports Q1 EPS $(0.23) vs $(0.24) Est., Sales $3.9M vs $5.5M Est.",2016-05-02 16:36:00-04:00,SGMO,neutral
1129625.0,Sangamo BioSciences To Present On ZFP Therapeutic Programs & Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy,2016-04-18 16:04:00-04:00,SGMO,neutral
1129626.0,Sangamo Sees FY16 Sales $20M-$25M vs $34M Est.,2016-02-09 16:05:00-05:00,SGMO,neutral
1129627.0,"Sangamo BioSciences Reports Q4 EPS $(0.20) vs $(0.21) Est., Sales $9.1M vs $9.9M Est.",2016-02-09 16:05:00-05:00,SGMO,neutral
1129628.0,10 Stocks Moving In Monday's Pre-Market Session,2016-02-08 08:20:00-05:00,SGMO,neutral
1129629.0,Sangamo BioSciences Reports FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I,2016-02-08 07:01:00-05:00,SGMO,neutral
1129630.0,Every Biotech Catalyst Wedbush Is Watching In 2016,2016-01-02 20:20:00-05:00,SGMO,neutral
1129631.0,Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016,2015-12-18 10:52:00-05:00,SGMO,neutral
1129632.0,Janney Capital Initiates Coverage on Sangamo BioSciences at Buy,2015-12-17 05:56:00-05:00,SGMO,neutral
1129633.0,Sangamo BioSciences Shows Phase 2 Clinical Data From Two SB-728-T HIV Studies,2015-12-11 07:03:00-05:00,SGMO,neutral
1129634.0,Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas,2015-12-08 08:29:00-05:00,SGMO,neutral
1129635.0,Sangamo BioSciences Shares Up ~4% On The Day With ASH Conf. Data On ZFP Therapeutic Programs For Hemophilia & Hemoglobinopathies Out,2015-12-07 10:39:00-05:00,SGMO,positive
1129636.0,Wells Fargo Initiates Coverage on Sangamo BioSciences at Outperform,2015-12-04 07:56:00-05:00,SGMO,positive
1129637.0,"Wedbush Reiterates Outperform Rating, $30 Price Target on Sangamo as Co. 'Cleared to Initiate In-Vivo Human Testing of its ZFN Based Protein Replacement Platform'",2015-12-02 06:58:00-05:00,SGMO,positive
1129638.0,Mid-Afternoon Market Update: Dow Climbs Over 100 Points; HF Financial Shares Rise On Merger News,2015-12-01 15:00:00-05:00,SGMO,positive
1129639.0,"Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B",2015-12-01 07:02:00-05:00,SGMO,neutral
1129640.0,"Sangamo Biosciences Reports Q3 Loss of $0.13/Share vs Loss of $0.24/Share Est., Sales $8.6M vs $13M Est.",2015-10-28 17:42:00-04:00,SGMO,negative
1129641.0,"Sangamo Shares Up 13+% Following Earlier New Buy Rating, $14 Price Target from Jefferies",2015-10-23 10:36:00-04:00,SGMO,positive
1129642.0,"Sangamo BioSciences Announces Presentation At The 2015 Stem Cell Meeting On The Mesa - 2:30pm PT on Wednesday, October 7, 2015",2015-09-30 16:02:00-04:00,SGMO,neutral
1129643.0,Sangamo BioSciences Reports Updated Clinical Data from ZFP Therapeutic® Program for HIV/AIDS at the 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy,2015-09-21 07:02:00-04:00,SGMO,neutral
1129644.0,UPDATE: Sangamo Biosciences Shares +25% Following Earlier Announcement of Unanimous Recombinant DNA Advisory Committee Approval of ZFP Therapeutic Phase 1 Study Protocol for First in Vivo Genome Editing Application,2015-09-10 12:24:00-04:00,SGMO,positive
1129645.0,Sangamo Biosciences Spiking Higher,2015-09-10 12:11:00-04:00,SGMO,neutral
1129646.0,Sangamo Report Unanimous Recombinant DNA Advisory Committee (RAC) Approval Of ZFP Therapeutic Phase 1 Study Protocol For First In Vivo Genome Editing Application,2015-09-10 07:02:00-04:00,SGMO,positive
1129647.0,Mid-Morning Market Update: Markets Gain; Campbell Soup Earnings Top Estimates,2015-09-03 10:29:00-04:00,SGMO,positive
1129648.0,"Sangamo, Shire Restructure Partnership to Accelerate Development of ZFP Therapeutics® for the Treatment of Hemophilia and Huntington's Disease",2015-09-02 07:01:00-04:00,SGMO,neutral
1129649.0,"Sangamo Reports Q2 Loss of $0.17/Share vs Loss of $0.13/Share Est., Sales $8.4M vs $15M Est.",2015-08-05 16:03:00-04:00,SGMO,negative
1129650.0,"Wednesday's After-Hours Movers: Five Below, FireEye And More",2015-06-03 17:59:00-04:00,SGMO,neutral
1129651.0,Sangamo Reports Presentation of New Data from Proprietary ZFP Therapeutic Programs for Lysosomal Storage Disorders at ASGCT,2015-05-18 07:21:00-04:00,SGMO,neutral
1129652.0,Sangamo BioSciences Provides Clinical Update On SB-728-T Program,2015-05-14 09:04:00-04:00,SGMO,neutral
1129653.0,Sangamo BioSciences Announces Joint Steering Committee Decision To Consolidate ZFP Therapeutic® Strategy For Hemoglobinopathies,2015-05-13 16:15:00-04:00,SGMO,neutral
1129654.0,Sangamo Biosciences Reports Joint Steering Committee Decision to Consolidate ZFP Therapeutic Strategy for Hemoglobinopathies,2015-05-13 16:14:00-04:00,SGMO,neutral
1129655.0,Biogen Or Bluebird: Which Will Lead In SCD?,2015-04-30 12:42:00-04:00,SGMO,neutral
1129656.0,Gene Therapy Stocks Take Beating On Bad News For Celladon,2015-04-27 13:49:00-04:00,SGMO,negative
1129657.0,"BMO Capital Initiates Coverage on Sangamo BioSciences at Outperform, Announces $19.00 PT",2015-04-22 17:23:00-04:00,SGMO,neutral
1129658.0,"Sangamo Biosciences Reports Q1 Loss of $0.08/Share vs Loss of $0.13/Share Est., Sales $13.49M vs $12.1M Est.",2015-04-22 16:14:00-04:00,SGMO,negative
1129659.0,Jefferies: 10 Buyout Targets To Own During The M&A Boom,2015-04-13 16:17:00-04:00,SGMO,neutral
1129660.0,Sangamo BioSciences Shares Move Higher; May be Attributed to Blog Post via @blinkX90,2015-03-03 13:12:00-05:00,SGMO,positive
1129661.0,US Stock Futures Edge Higher Ahead Of Economic Data,2015-02-26 07:57:00-05:00,SGMO,neutral
1129662.0,Sangamo BioSciences Reports Positive Clinical Data from Trial of ZFP Therapeutic Designed to Provide Functional Control of HIV,2015-02-26 07:11:00-05:00,SGMO,positive
1129663.0,Sangamo BioSciences Announces FDA Acceptance of IND Application for New HIV/AIDS Clinical Trial Using ZFN-Modification of Hematopoietic Stem Cells,2015-02-26 07:10:00-05:00,SGMO,positive
1129664.0,Mid-Day Market Update: Interxion Surges On Merger Agreement With TelecityGroup; Marketo Shares Slide,2015-02-11 13:16:00-05:00,SGMO,positive
1129665.0,"Sangamo Reports Q4 Loss of $0.06/Share, Sales $15M; Sees FY15 Sales $60M-$70M",2015-02-10 16:13:00-05:00,SGMO,negative
1129666.0,Sangamo BioSciences Announces FDA Acceptance of IND to Initiate Clinical Trial of  ZFP Therapeutic for Beta-Thalassemia,2015-02-04 07:08:00-05:00,SGMO,positive
1129667.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,SGMO,neutral
1129668.0,Sangamo Biosciences Shares Spike Higher,2014-12-29 13:30:00-05:00,SGMO,positive
1129669.0,Is Sangamo The Next Biotech Stock To Break Out?,2014-12-17 15:56:00-05:00,SGMO,neutral
1129670.0,Sangamo Shares Spike Higher,2014-12-09 11:24:00-05:00,SGMO,positive
1129671.0,Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms,2014-11-19 07:00:00-05:00,SGMO,neutral
1129672.0,"Sangamo BioSciences, Inc. Reports Q3 EPS of $(0.11) vs $(0.14) Est; Revenue of $12.40M vs $8.27M Est",2014-10-22 16:02:00-04:00,SGMO,neutral
1129673.0,Sangamo BioSciences ZFP Therapeutic Program In HIV/AIDS Featured At Three Major Scientific Conferences In October 2014,2014-10-16 07:08:00-04:00,SGMO,neutral
1129674.0,Dow Finishes Down 100+ Points For Second Consecutive Day,2014-09-23 16:57:00-04:00,SGMO,neutral
1129675.0,Dow Down 0.6%; CarMax Shares Fall After Q2 Results,2014-09-23 15:13:00-04:00,SGMO,positive
1129676.0,Shares of Sangamo Ticking Higher as CNBC Mentioning Early-Morning New Buy Rating and $22 Price Target from Jefferies,2014-09-23 14:35:00-04:00,SGMO,positive
1129677.0,Ascena Retail Drops On Downbeat Earnings; CF Industries Shares Gain,2014-09-23 12:43:00-04:00,SGMO,positive
1129678.0,Markets Mixed; Carnival Profit Tops Street View,2014-09-23 11:20:00-04:00,SGMO,positive
1129679.0,Morning Market Movers ,2014-09-23 09:38:00-04:00,SGMO,neutral
1129680.0,"Jefferies Initiates Coverage on Sangamo BioSciences, Inc. at Buy, Announces $22.00 PT",2014-09-23 07:22:00-04:00,SGMO,neutral
1129681.0,"Sangamo Biosciences, Inc. Is Preparing To Drop Big",2014-09-10 16:40:00-04:00,SGMO,negative
1129682.0,"Sangamo Reports Target Date for First IND for In Vivo ZFN Genome-Editing Platform, Sees Submission in Q2'15, Sees IND for Hemophilia by Year End '15",2014-09-10 07:06:00-04:00,SGMO,neutral
1129683.0,"J.P. Morgan Sees Sangamo Biosciences, Inc. As Attractive Investment Opportunity",2014-09-09 09:20:00-04:00,SGMO,positive
1129684.0,UPDATE: J.P. Morgan Initiates Coverage On Sangamo Biosciences On Potentially Disruptive Future,2014-08-01 11:38:00-04:00,SGMO,negative
1129685.0,Benzinga's Top Initiations,2014-08-01 09:22:00-04:00,SGMO,positive
1129686.0,JP Morgan Initiates Sangamo BioSciences With Overweight,2014-08-01 08:44:00-04:00,SGMO,neutral
1129687.0,"JP Morgan Initiates Coverage on Sangamo BioSciences, Inc. at Overweight, Announces $22.00 PT",2014-08-01 06:47:00-04:00,SGMO,neutral
1129688.0,"Sangamo BioSciences, Inc. Reports Q2 EPS of $(0.10) vs $(0.14) Est; Revenue of $10.40M vs $7.84M Est",2014-07-23 17:05:00-04:00,SGMO,neutral
1129689.0,"Events Scheduled for Week of Jun 23rd to Jun 27th, 2014",2014-06-23 18:25:00-04:00,SGMO,neutral
1129690.0,"Sangamo Announces Co., City of Hope Win Strategic Partnership from California Institute for Regenerative Medicine to Support Clinical Trial of Stem-Cell Based ZFP Therapeutic for HIV/AIDS",2014-05-30 07:09:00-04:00,SGMO,positive
1129691.0,Sangamo Publishes Preclinical Data Showing Gene Correction in SCID-X1 Human Hematopoietic Stem Cells,2014-05-28 13:36:00-04:00,SGMO,neutral
1129692.0,Sangamo BioSciences Clinical Update on SB-728-T Program and Progress in Other ZFP Applications at ASGCT,2014-05-27 07:08:00-04:00,SGMO,positive
1129693.0,Sangamo BioSciences to Present Data on ZFP Therapeutic Applications and Developments at ASGCT,2014-05-14 08:06:00-04:00,SGMO,neutral
1129694.0,Mid-Day Market Update: Nike Drops On Cautious Forecast; Endocyte Shares Spike Higher,2014-03-21 12:44:00-04:00,SGMO,positive
1129695.0,Sangamo BioSciences Prices 4.44M Share Offering at $22.50/Share,2014-03-20 21:43:00-04:00,SGMO,positive
1129696.0,Sangamo BioSciences Announces $100M Public Offering of Common Stock,2014-03-19 16:01:00-04:00,SGMO,neutral
1129697.0, Sangamo Biosciences CEO Lanphier: 'One of the Tools we Use is Whole Genome Sequencing',2014-03-06 18:21:00-05:00,SGMO,neutral
1129698.0, Sangamo Biosciences CEO Lanphier: 'We are in a Strong Financial Position',2014-03-06 18:20:00-05:00,SGMO,positive
1129699.0," Sangamo Biosciences CEO Lanphier: 'We are Not Trying to Treat the Disease, We are Trying to Change the DNA so we can Cure It'",2014-03-06 18:19:00-05:00,SGMO,negative
1129700.0,Jim Cramer Interviews CEO  Edward O. Lanphieri of Sangamo Biosciences on Mad Money,2014-03-06 18:17:00-05:00,SGMO,negative
1129701.0,"Mid-Afternoon Market Update: Markets Turn Up From the Lows, Fuel Cell Companies Show Weakness",2014-03-06 15:52:00-05:00,SGMO,negative
1129702.0,Mid-Day Market Update: Costco Shares Decline After Weak Quarterly Results; Stage Stores Spikes Higher,2014-03-06 12:28:00-05:00,SGMO,negative
1129703.0,"Morning Gainers for Mar. 6, 2014: PXLW, SGMO, ERII, RGSE, NAVB, PSTI",2014-03-06 11:08:00-05:00,SGMO,neutral
1129704.0,Benzinga's Volume Movers,2014-03-06 10:38:00-05:00,SGMO,neutral
1129705.0,Mid-Morning Market Update: Markets Open Higher; Staples Plans To Close 225 Stores,2014-03-06 10:21:00-05:00,SGMO,neutral
1129706.0,Benzinga's Top #PreMarket Gainers,2014-03-06 08:11:00-05:00,SGMO,positive
1129707.0,Sangamo Shares Spike Higher as Co Announces First-In-Man Study Of Genome Editing Using Sangamo's ZFN Technology Published In New England Journal Of Medicine,2014-03-05 17:31:00-05:00,SGMO,positive
1129708.0,Option Alert; Sangamo July $25 Call; Aug $47 Call; 1m673 Contract Trade Between Bid and Ask @$2.35; Currently $18.09,2014-03-03 11:47:00-05:00,SGMO,positive
1129709.0,Sangamo Biosciences Spikes Lower,2014-02-26 13:33:00-05:00,SGMO,negative
1129710.0,Sangamo Files Automatic Mixed Securities Shelf,2014-02-25 16:54:00-05:00,SGMO,positive
1129711.0,"Sangamo BioSciences, Inc. Sees FY2014 Sales $45.0M-50.0M vs $35.50M Est",2014-02-11 16:24:00-05:00,SGMO,neutral
1129712.0,"Sangamo BioSciences, Inc. Reports Q4 EPS of $(0.13) vs $(0.10) Est; Revenue of $6.87M vs $5.69M Est",2014-02-11 16:05:00-05:00,SGMO,neutral
1129713.0,"Option Alert: Sangamo BioSciences Jan 2015 $15 Call; 30,000 Contract Trade Between Bid and Ask @$6.00; Currently $18.81",2014-01-29 10:41:00-05:00,SGMO,positive
1129714.0,"Option Alert: Sangamo BioSciences Jan 2015 $25 Call; 2,500 Contract Trade Between Bid and Ask @$2.85; Currently $19.66",2014-01-17 13:59:00-05:00,SGMO,positive
1129715.0,Sangamo Says has Strong Cash Position,2014-01-16 14:24:00-05:00,SGMO,positive
1129716.0,Sangamo Biosciences Exec Presentation at JP Morgan Healthcare Conf. Just Getting Underway,2014-01-16 14:18:00-05:00,SGMO,positive
1129717.0,Sangamo BioSciences Spikes Hgher,2014-01-16 14:14:00-05:00,SGMO,neutral
1129718.0,Market Wrap For January 9: All Eyes on Tomorrow's Job Report,2014-01-09 16:43:00-05:00,SGMO,neutral
1129719.0,Mid-Day Market Update: U.S. Stocks Turn Red; Bed Bath & Beyond Shares Decline On Weak Q3 Earnings,2014-01-09 12:46:00-05:00,SGMO,negative
1129720.0,Benzinga's Volume Movers,2014-01-09 10:28:00-05:00,SGMO,neutral
1129721.0,Stocks Hitting 52-Week Highs,2014-01-09 10:23:00-05:00,SGMO,neutral
1129722.0,Morning Market Movers ,2014-01-09 10:05:00-05:00,SGMO,neutral
1129723.0,Benzinga's Top #PreMarket Gainers,2014-01-09 08:14:00-05:00,SGMO,positive
1129724.0,"Sangamo BioSciences, Biogen Partnership to Develop Novel Therapies for Sickle Cell Disease, Beta-Thalassemia",2014-01-09 07:11:00-05:00,SGMO,positive
1129725.0,Sangamo Presents Data from In Vivo Protein Replacement Platform at ASH,2013-12-10 07:18:00-05:00,SGMO,neutral
1129726.0,"Stocks to Watch for December 09, 2013",2013-12-09 17:00:00-05:00,SGMO,neutral
1129727.0,Sangamo Presents Data From ZFP Therapeutic Program for Treatment Of Sickle Cell Disease And Beta-Thalassemia at ASH,2013-12-09 07:10:00-05:00,SGMO,neutral
1129728.0,Sangamo Biosciences Reports Presentation of Clinical Data from Alzheimer's Program,2013-11-15 07:03:00-05:00,SGMO,neutral
1129729.0,Sangamo BioSciences Presentats Positive Data from Alzheimer's Disease Treatment,2013-11-15 07:02:00-05:00,SGMO,positive
1129730.0,US Stock Futures Up Ahead Of Factory Orders Data,2013-11-04 07:30:00-05:00,SGMO,neutral
1129731.0,Sangamo Presents Positive Clinical Data from SB-728-T HIV Study ,2013-11-04 07:04:00-05:00,SGMO,positive
1129732.0,Sangamo BioSciences Reports Study Results from SB-728-T for HIV Showed Reduction,2013-11-04 07:02:00-05:00,SGMO,neutral
1129733.0,Sangamo BioSciences Presents Promising HIV Study Data,2013-10-28 07:03:00-04:00,SGMO,positive
1129734.0,"Sangamo BioSciences, Inc. Reports Q3 EPS of $(0.11), Inline; Revenue of $5.71M vs $5.52M Est",2013-10-23 16:11:00-04:00,SGMO,neutral
1129735.0,Sangamo BioSciences Closes Offering of 6.1M Shares at $10.58/Share,2013-09-23 12:01:00-04:00,SGMO,positive
1129736.0,Streetsweeper Report: 'Sangamo: A fiery biotech with a product poised to go down in flames?'',2013-09-19 12:43:00-04:00,SGMO,negative
1129737.0,TheStreetSweeper releases its investigative report on Sangamo Biosciences,2013-09-19 12:41:00-04:00,SGMO,neutral
1129738.0,Sangamo Biosciences Prices Offering of 6.1M Share at $10.58/Share,2013-09-18 09:02:00-04:00,SGMO,positive
1129739.0,Benzinga's Top Pre-Market Losers,2013-09-18 08:13:00-04:00,SGMO,negative
1129740.0,Sangamo Biosciences Reports Offering of Common Stock,2013-09-17 16:02:00-04:00,SGMO,neutral
1129741.0,Benzinga's Top Pre-Market Gainers,2013-09-13 08:46:00-04:00,SGMO,positive
1129742.0,Sangamo BioSciences Announces Data from Trial of SB-728-T Shows Sustained Cut of Viral Load At or Below Detect Limit,2013-09-12 17:03:00-04:00,SGMO,negative
1129743.0,Sangamo to Buy Ceregene,2013-08-26 16:03:00-04:00,SGMO,neutral
1129744.0,Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology ,2013-08-14 07:01:00-04:00,SGMO,neutral
1129745.0,"Sangamo BioSciences, Inc. Reports Q2 EPS of $(0.10) vs $(0.13) Est; Revenue of $6.93M vs $4.77M Est",2013-07-24 16:27:00-04:00,SGMO,neutral
1129746.0,Technology Made By Sangamo Biosciences Used In Gene Splicing to Find Cure For Down Syndrome Showing Success - Nature,2013-07-17 13:04:00-04:00,SGMO,positive
1129747.0,"Cowen & Company Initiates Coverage on Sangamo BioSciences, Inc. at Outperform",2013-06-17 08:43:00-04:00,SGMO,neutral
1129748.0,Sangamo BioSciences Receives $6.4M Strategic Partnership Award from CIRM,2013-05-24 07:02:00-04:00,SGMO,positive
1129749.0,UPDATE: Sangamo Highlights Encouraging Preliminary Anti-Viral HIV Data during Treatment Interruption in Ongoing SB-728-T Phase 2 Trials,2013-05-15 10:21:00-04:00,SGMO,positive
1129751.0,"Sangamo BioSciences, Inc. Reports Q1 EPS of $(0.13) vs $(0.16) Est; Revenue of $4.62M vs $3.79M Est",2013-05-08 16:24:00-04:00,SGMO,neutral
1129752.0,"Stocks to Watch for April 12, 2013",2013-04-12 08:22:00-04:00,SGMO,neutral
1129753.0,"Sangamo, Alnylam Shares Spike Higher on Positive Jim Cramer/Mad Money Comments",2013-04-03 18:38:00-04:00,SGMO,positive
1129754.0,"JMP Securities Initiates Coverage on Sangamo BioSciences, Inc. at Market Outperform, Announces $16.00 PT",2013-03-28 08:45:00-04:00,SGMO,positive
1129755.0,Report of 14 Adults 'Cured' of HIV -NewScientist,2013-03-15 06:27:00-04:00,SGMO,neutral
1129756.0,"UPDATE: Wedbush Raises PT to $13 on Sangamo BioSciences on HIV Progress, Time Value",2013-03-07 10:50:00-05:00,SGMO,positive
1129757.0,"Wedbush Maintains Outperform on Sangamo BioSciences, Inc., Raises PT to $13.00",2013-03-07 08:38:00-05:00,SGMO,neutral
1129758.0,Sangamo Presenting New Data at CROI 2013 Which Demonstrates Persistant Immune System Improvements AFter Treatment with ZFN's SB-728-T,2013-03-06 11:48:00-05:00,SGMO,positive
1129759.0,"Increased Volatility in SGMO as Traded 2,022 April $10 Puts Over 307 Open Interest; Shares Marking Fresh Session Low",2013-03-05 12:53:00-05:00,SGMO,positive
1129760.0,Sangamo Biosciences Spokesperson Says HIV Cure in Baby is Great News; Says This is More of a Problem in Developing World than in US,2013-03-04 13:01:00-05:00,SGMO,positive
1129761.0,HIV Infected Baby 'Cured' with Aggressive Drug Treatment -NYT,2013-03-03 17:50:00-05:00,SGMO,negative
1129762.0,"Lazard Capital Markets Initiates Coverage on Sangamo BioSciences, Inc. at Buy, Announces $16.00 PT",2013-02-28 07:46:00-05:00,SGMO,neutral
1129763.0,UPDATE: Burrill Initiates Sangamo Biosciences at Market Outperform ,2013-02-19 08:49:00-05:00,SGMO,neutral
1129764.0,"Burrill Initiates Coverage on Sangamo BioSciences, Inc. at Market Outperform, Announces $28.00 PT",2013-02-19 07:24:00-05:00,SGMO,neutral
1129765.0,Option Alert: Sangamo Biosciences August 17 Call: 500 Contracts Traded vs 25 Open Interest; Currently $8.51,2013-02-07 11:44:00-05:00,SGMO,positive
1129766.0,"Sangamo BioSciences, Inc. Reports Q4 EPS of $(0.07); Revenue of $8.90M vs $4.70M Est",2013-02-06 16:16:00-05:00,SGMO,neutral
1129767.0,Stocks Hitting 52-Week Highs,2013-01-11 10:09:00-05:00,SGMO,neutral
1129768.0,Stocks Hitting 52-Week Highs,2013-01-10 10:06:00-05:00,SGMO,neutral
1129769.0,Sangamo BioSciences Says Will Provide Update on ZFP Therapeutics at 5pm,2012-12-06 16:10:00-05:00,SGMO,neutral
1129770.0,"Sangamo Guides FY Revenue $18-20M, Had Seen $14-18M",2012-10-24 16:48:00-04:00,SGMO,neutral
1129771.0,Sangamo Biosciences Reports Q3 EPS $-0.11 vs $-0.14 Est; Revenues $4.9M vs $3.80M Est,2012-10-24 16:21:00-04:00,SGMO,neutral
1129772.0,Sangamo BioSciences Announces Presentation of Clinical Data from ZFP Therapeutic® for HIV/AIDS at ICAAC 2012 ,2012-09-10 12:31:00-04:00,SGMO,neutral
1129773.0,UPDATE: Piper Jaffray Downgrades Sangamo BioSciences to Underweight on Limited Clinical Drivers   ,2012-07-02 07:17:00-04:00,SGMO,negative
1129774.0,"Piper Jaffray Downgrades Sangamo Biosciences from Neutral to Underweight, Maintains PT at $4",2012-07-02 05:57:00-04:00,SGMO,neutral
1129775.0,UPDATE: GARP Research & Securities Drops Coverage on Sangamo Biosciences on Termination of Neuropathy Treatment Efforts  ,2012-06-20 07:59:00-04:00,SGMO,positive
1129776.0,Sangamo Biosciences Trading 3.6% Higher on Heavy Volume; Currently at $5.14,2012-03-08 15:24:00-05:00,SGMO,neutral
1129777.0,"Sangamo Presents New Clinical Data at CROI 2012 Demonstrating Persistent Positive Effects of ZFN Therapeutic® for ""Functional Cure"" of HIV/AIDS ",2012-03-08 15:23:00-05:00,SGMO,positive
1129778.0,Weekly Traders Homework: Small-Caps Correcting (w/ Economic Calendar and Stock Radar),2012-03-05 00:10:00-05:00,SGMO,neutral
1129779.0,Weekly Traders Homework: Oil Is The Hot Theme (w/ Economic Calendar and Stock Radar),2012-02-27 00:26:00-05:00,SGMO,neutral
1129780.0,Notable Call Options Activity in Sangamo BioSciences,2012-02-21 10:37:00-05:00,SGMO,neutral
1129781.0,Weekly Traders Homework: Contrarian Indicators Flashing (w/ Economic Calendar and Stock Radar),2012-02-20 23:47:00-05:00,SGMO,neutral
1129782.0,Sangamo Biosciences Trading 23.7% Higher on Heavy Volume; Currently at $5.2,2012-02-17 15:27:00-05:00,SGMO,neutral
1129783.0,Sangamo Biosciences Reports Q4 EPS $(0.12) vs $(0.12) Est; Revenues $4.75M vs $3.41M Est			,2012-02-08 16:04:00-05:00,SGMO,neutral
1129784.0,Piper Jaffray Upgrades Sangamo BioSciences to Neutral,2012-02-01 11:09:00-05:00,SGMO,neutral
1129785.0,Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases ,2012-02-01 07:03:00-05:00,SGMO,neutral
1129786.0,Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials  ,2012-01-09 07:02:00-05:00,SGMO,neutral
1129787.0,"Wedbush Reiterates Sangamo BioSciences Outperform, $9 FVE",2011-12-13 13:17:00-05:00,SGMO,neutral
1129788.0,Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic Program in Hemophilia B at American Society for Hematology Meeting ,2011-12-13 07:02:00-05:00,SGMO,neutral
1129789.0,Sangamo Biosciences Reports Q3 EPS $(0.18) vs $(0.16) Est; Revenues $1.86M vs $2.82M Est		,2011-10-25 16:16:00-04:00,SGMO,neutral
1129790.0,Sangamo BioSciences Announces Publication in Nature of Gene Correction Strategy for Alpha 1-Antitrypsin Deficiency  ,2011-10-13 07:01:00-04:00,SGMO,neutral
1129791.0,Market Has Broken Two Critical Levels  10-03-2011,2011-10-03 15:38:00-04:00,SGMO,negative
1129792.0,Piper Jaffray Lowers PT on Sangamo BioSciences to $2,2011-10-03 10:40:00-04:00,SGMO,negative
1129793.0,Notable Call Options Activity in Sangamo BioSciences,2011-10-03 10:30:00-04:00,SGMO,neutral
1129794.0,UPDATE: Sangamo BioSciences Conference Call to Begin at 8:30am,2011-10-03 08:30:00-04:00,SGMO,neutral
1129795.0,"Financial Breakfast: Morning News Summary for October 3, 2011",2011-10-03 07:42:00-04:00,SGMO,neutral
1129796.0,Sangamo BioSciences Resumes Trading,2011-10-03 07:35:00-04:00,SGMO,neutral
1129797.0,PREVIEW: Sangamo BioSciences to Resume Trading at 7:30am,2011-10-03 07:18:00-04:00,SGMO,neutral
1129798.0,Sangamo BioSciences Announces Phase 2b Trial of SB-509 in Diabetic Neuropathy Did Not Meet Key Study Endpoints ,2011-10-03 07:02:00-04:00,SGMO,neutral
1129799.0,Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Diabetic Neuropathy Trial Monday 8:30am,2011-09-30 18:13:00-04:00,SGMO,neutral
1129800.0,Sangamo BioSciences Presents Clinical Data from ZFN Therapeutic for HIV/AIDS,2011-09-18 15:50:00-04:00,SGMO,neutral
1129801.0,Notable Call Options Activity in Sangamo BioSciences,2011-08-30 11:56:00-04:00,SGMO,neutral
1129802.0,Notable Call Options Activity in Sangamo BioSciences,2011-08-23 10:12:00-04:00,SGMO,neutral
1129803.0,Options Brief: Sangamo BioSciences ,2011-08-03 14:19:00-04:00,SGMO,neutral
1129804.0,Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease Technology  ,2011-07-21 07:13:00-04:00,SGMO,positive
1129805.0,Benzingas Top Pre-Market NASDAQ Gainers,2011-06-27 08:13:00-04:00,SGMO,positive
1129806.0,Benzinga's Top Pre-Market NASDAQ Gainers,2011-05-23 08:20:00-04:00,SGMO,positive
1129807.0,Wedbush Lowers Fair Market Value To $12 On SGMO,2011-04-14 08:56:00-04:00,SGMO,positive
1129808.0,"Afternoon Market Top Percentage Gainers and Losers (CAAS, GENE, SYMX, TPX, GY, SCOK, LIWA, IDIX, HERO, SGMO)",2011-04-08 12:01:00-04:00,SGMO,positive
1129809.0,Options Brief: Sangamo BioSciences (SGMO),2011-04-08 10:35:00-04:00,SGMO,neutral
1129810.0,"Morning Market Top Percentage Gainers and Losers (CONN, TPX, EXPE, CAAS, QLTI, SCOK, IDIX, HERO, SGMO, YONG)",2011-04-08 10:05:00-04:00,SGMO,positive
1129811.0,Sangamo Announces Pricing of Public Offering of Common Stock at $4.70 per Share,2011-04-08 09:06:00-04:00,SGMO,positive
1129812.0,"Pre-Market Top Percentage Gainers and Losers (EXPE, STX, NSPI, INTC, IMGN, CONN, SCOK, HERO, IDIX, SGMO, CHBT) ",2011-04-08 08:48:00-04:00,SGMO,positive
1129813.0,"Benzinga's Top Pre-Market NASDAQ Losers (HERO, IDIX, XING, SGMO)",2011-04-08 08:18:00-04:00,SGMO,negative
1129814.0,"Stocks To Watch For April 8 (STX, SGMO, TPX, EXPE, LAKE)",2011-04-08 00:11:00-04:00,SGMO,neutral
1129815.0,Sangamo Announces Public Offering Of 6.7M Shares,2011-04-07 16:13:00-04:00,SGMO,positive
1129816.0,Options Brief: Sangamo BioSciences (SGMO),2011-02-14 11:17:00-05:00,SGMO,neutral
1129817.0,Calls Purchased on Sangamo BioSciences (SGMO),2011-02-14 10:26:00-05:00,SGMO,neutral
1129818.0,Sangamo BioSciences Shares Surge 9.6% (SGMO),2010-12-16 14:25:00-05:00,SGMO,positive
1129819.0,"Benzinga's Top Pre-Market NASDAQ Gainers (KUTV, SGMO, FNSR, WTSLA)",2010-12-02 08:48:00-05:00,SGMO,positive
1129820.0,"Benzinga's Top Pre-Market NASDAQ Gainers (SGMO, AMZN, YHOO, AAPL)",2010-11-29 08:15:00-05:00,SGMO,positive
1129821.0,Piper Jaffray Maintains Underweight On Sangamo BioSciences  (SGMO),2010-11-18 07:16:00-05:00,SGMO,neutral
1129822.0,Piper Jaffray Maintains Underweight On Sangamo BioSciences  (SGMO),2010-10-28 07:17:00-04:00,SGMO,neutral
1129823.0,Sangamo BioSciences Reports Third Quarter 2010 Financial Results: Loss of $0.19,2010-10-27 16:29:00-04:00,SGMO,negative
1129824.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,SGMO,positive
1129825.0,"Biggest Losers (MERX, AAI, SGMO, CAR, GRS)",2009-10-07 11:33:00-04:00,SGMO,negative
